Cargando…
CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
BACKGROUND: Comparative genetic and biological studies on malignant tumor counterparts in human beings and laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocytes and plasma cells such as Burkitt lymphoma (BL) and multiple myeloma (MM). MET...
Autores principales: | Han, Seong-Su, Tompkins, Van S, Son, Dong-Ju, Han, Sangwoo, Yun, Hwakyung, Kamberos, Natalie L, Dehoedt, Casey L, Gu, Chunyan, Holman, Carol, Tricot, Guido, Zhan, Fenghuang, Janz, Siegfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383050/ https://www.ncbi.nlm.nih.gov/pubmed/25838973 http://dx.doi.org/10.1186/s40164-015-0005-2 |
Ejemplares similares
-
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018) -
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019) -
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018) -
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015) -
Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)